aap Implantate Valuation

Is AAQ1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AAQ1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AAQ1's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AAQ1's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AAQ1?

Key metric: As AAQ1 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for AAQ1. This is calculated by dividing AAQ1's market cap by their current revenue.
What is AAQ1's PS Ratio?
PS Ratio	1.9x
Sales	€11.96m
Market Cap	€22.40m

AAQ1 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.1x
Enterprise Value/EBITDA	-8.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does AAQ1's PS Ratio compare to its peers?

The above table shows the PS ratio for AAQ1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5.6x
NN6 NanoRepro	5.3x	n/a	€18.9m
GME Geratherm Medical	0.9x	1.9%	€16.5m
AUG Audientes	12.6x	n/a	€6.9m
PUS PULSION Medical Systems	3.8x	n/a	€134.4m
AAQ1 aap Implantate	1.9x	n/a	€22.4m

Price-To-Sales vs Peers: AAQ1 is good value based on its Price-To-Sales Ratio (1.9x) compared to the peer average (3.3x).

Price to Sales Ratio vs Industry

How does AAQ1's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 Companies	Price / Sales	Estimated Growth	Market Cap
DRW3 Drägerwerk KGaA	0.2x	4.2%	US$836.09m
PHH2 Paul Hartmann	0.3x	n/a	US$779.09m
U4W0 Quotient	0.07x	n/a	US$2.78m
MF6 MagForce	0.3x	n/a	US$404.27k

No more companies available in this PS range

4 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: AAQ1 is good value based on its Price-To-Sales Ratio (1.9x) compared to the European Medical Equipment industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is AAQ1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AAQ1 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.9x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate AAQ1's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

LNA Santé

€244.9m

Engages in the management and operation of health establishments.

2N3

€23.30

-5.3%

19.1%

Shandong Weigao Group Medical Polymer

HK$19.8b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.51

-10.5%

-38.6%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

0.5%

-82.5%